These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1724 related articles for article (PubMed ID: 30485437)
1. Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations. Lin YT; Chen JS; Liao WY; Ho CC; Hsu CL; Yang CY; Chen KY; Lee JH; Lin ZZ; Shih JY; Yang JC; Yu CJ Int J Cancer; 2019 Jun; 144(11):2887-2896. PubMed ID: 30485437 [TBL] [Abstract][Full Text] [Related]
4. Survival benefits from afatinib compared with gefitinib and erlotinib among patients with common EGFR mutation in first-line setting. Kwok WC; Ho JCM; Tam TCC; Ip MSM; Lam DCL Thorac Cancer; 2022 Jul; 13(14):2057-2063. PubMed ID: 35668712 [TBL] [Abstract][Full Text] [Related]
5. Clinical factors associated with treatment outcomes in EGFR mutant non-small cell lung cancer patients with brain metastases: a case-control observational study. Chen YH; Chen YF; Chen CY; Shih JY; Yu CJ BMC Cancer; 2019 Oct; 19(1):1006. PubMed ID: 31655564 [TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer harboring uncommon EGFR mutations: Real-world data from Taiwan. Chang JW; Huang CY; Fang YF; Chang CF; Yang CT; Kuo CS; Hsu PC; Wu CE Thorac Cancer; 2023 Jan; 14(1):12-23. PubMed ID: 36424878 [TBL] [Abstract][Full Text] [Related]
7. Real-world study of afatinib in first-line or re-challenge settings for patients with EGFR mutant non-small cell lung cancer. Tanaka H; Taima K; Itoga M; Ishioka Y; Baba K; Shiratori T; Sakamoto H; Tsuchiya J; Nakagawa H; Hasegawa Y; Yasugahira H; Okudera K; Takanashi S; Tasaka S Med Oncol; 2019 May; 36(6):57. PubMed ID: 31089973 [TBL] [Abstract][Full Text] [Related]
8. Comparison of Effectiveness of Gefitinib, Erlotinib, and Afatinib in Advanced Non-small Cell Lung Cancer Patients with EGFR Mutation Positive in Indonesian Population. Sutandyo N; Hanafi A; Jayusman M Zhongguo Fei Ai Za Zhi; 2019 Sep; 22(9):562-567. PubMed ID: 31526459 [TBL] [Abstract][Full Text] [Related]
10. Repeat biopsy procedures and T790M rates after afatinib, gefitinib, or erlotinib therapy in patients with lung cancer. Lee K; Kim Y; Jung HA; Lee SH; Ahn JS; Ahn MJ; Park K; Choi YL; Sun JM Lung Cancer; 2019 Apr; 130():87-92. PubMed ID: 30885357 [TBL] [Abstract][Full Text] [Related]
11. Comparing the effectiveness of different EGFR-TKIs in patients with EGFR mutant non-small-cell lung cancer: A retrospective cohort study in Taiwan. Hsieh YY; Fang WT; Lo YW; Chen YH; Chien LN Int J Cancer; 2020 Aug; 147(4):1107-1116. PubMed ID: 31854456 [TBL] [Abstract][Full Text] [Related]
12. Incidence of T790M in Patients With NSCLC Progressed to Gefitinib, Erlotinib, and Afatinib: A Study on Circulating Cell-free DNA. Del Re M; Petrini I; Mazzoni F; Valleggi S; Gianfilippo G; Pozzessere D; Chella A; Crucitta S; Rofi E; Restante G; Miccoli M; Garassino MC; Danesi R Clin Lung Cancer; 2020 May; 21(3):232-237. PubMed ID: 31735523 [TBL] [Abstract][Full Text] [Related]
13. The Role of Brain Radiotherapy before First-Line Afatinib Therapy, Compared to Gefitinib or Erlotinib, in Patients with EGFR-Mutant Non-Small Cell Lung Cancer. Jung HA; Park S; Lee SH; Ahn JS; Ahn MJ; Sun JM Cancer Res Treat; 2023 Apr; 55(2):479-487. PubMed ID: 36596729 [TBL] [Abstract][Full Text] [Related]
14. Do patient characteristics affect EGFR tyrosine kinase inhibitor treatment outcomes? A network meta-analysis of real-world survival outcomes of East Asian patients with advanced non-small cell lung cancer treated with first-line EGFR-TKIs. Chang HC; Wang CC; Tseng CC; Huang KT; Chen YM; Chang YP; Lai CH; Fang WF; Lin MC; Chuang HY Thorac Cancer; 2023 Nov; 14(32):3208-3216. PubMed ID: 37737541 [TBL] [Abstract][Full Text] [Related]
15. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Nguyen KS; Kobayashi S; Costa DB Clin Lung Cancer; 2009 Jul; 10(4):281-9. PubMed ID: 19632948 [TBL] [Abstract][Full Text] [Related]
16. Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC. Ju JS; Huang AC; Tung PH; Huang CH; Chiu TH; Wang CC; Ko HW; Chung FT; Hsu PC; Fang YF; Guo YK; Kuo CS; Yang CT Sci Rep; 2023 Nov; 13(1):20323. PubMed ID: 37989860 [TBL] [Abstract][Full Text] [Related]
17. Audit of Molecular Mechanisms of Primary and Secondary Resistance to Various Generations of Tyrosine Kinase Inhibitors in Known Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Cancer Patients in a Tertiary Centre. Suryavanshi M; Jaipuria J; Mattoo S; Dhandha S; Khatri M Clin Oncol (R Coll Radiol); 2022 Nov; 34(11):e451-e462. PubMed ID: 35810049 [TBL] [Abstract][Full Text] [Related]